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Editorial on the Research Topic
Nomenclature - Avoiding Babylonian Speech Confusion in Present Day Immunology
INTRODUCTION
The complexity of the immune system at the gene, protein, cell, and organism levels continues to
provide a major challenge. Genomic landscaping, single-cell analysis and mass data acquisition
including genome, transcriptome, metabolome, and proteome have now added new levels of
complexity. With the rapid progress in these and other fields of immunology, it has become more
important than ever to agree on uniform nomenclatures, i.e. to agree on how to name novel genes,
proteins, cells, and biological reagents.
Names given initially might, in retrospect, not always be logical. For example, tumor necrosis
factor (TNF) was named on the basis of the observation of central necrosis in an experimental
subcutaneous mouse tumor model (1). It was only after many unsuccessful studies in cancer, that
eventually the role of TNF as a master cytokine in inflammation emerged. By that time, it was too
late to rename the molecule because that would cause renewed confusion.
Another cytokine has been successfully renamed. Interleukin-6 was initially known as B-cell
Stimulatory Factor 2, Cytotoxic T lymphocyte Differentiation Factor, Hybridoma Growth Factor,
Hepatocyte Stimulating Factor, and Interferon Beta-2. Obviously, such usage of different names for
the same item can lead to confusion and may hinder progress in the field. These two examples
demonstrate the need for a consensus nomenclature, which is timely applied.
Indeed, the impacts of early consensus nomenclature are enormous, and the immunological
community has an excellent track record of conducting worldwide cooperative efforts on
nomenclature issues (2). Remarkable examples of these include nomenclature for antigen
receptor (IG and TR) genes (3), cytokines and chemokines and their receptors (4), as well as
allergens (5), cell types (6, 7) and the CD nomenclature for monoclonal antibodies (8).org December 2020 | Volume 11 | Article 6211001
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consensus regarding classification of leukocytes. The monocyte
nomenclature proposal in 2010 defined the population of
“intermediate monocytes” (7), resulting in >2000 returns for
this term under Google Scholar. Furthermore, consensus
nomenclature has been defined for innate lymphoid cell (ILC)
subsets (6), which will undoubtedly drive discoveries into their
roles in tissue homeostasis, morphogenesis, metabolism, repair,
and regeneration.
With the many achievements reached in the past 40 decades,
there is a wealth of experience to draw upon, especially within the
subcommittees of the Nomenclature Committee of the
International Union of Immunological Societies (IUIS; https://
iuis.org/). The IUIS Nomenclature Committee is fostering
nomenclature efforts by providing a platform that currently
includes the activities of altogether 11 nomenclature
subcommittees (https://iuis.org/committees/nom/). Each
subcommittee consists of a representative group of experts in
the field, independently decides on nomenclature on the basis of
consensus, and is typically endorsed by IUIS and one or more
sister societies (e.g. Allergens by AAAI/EAACI/IUIS,
Complement by ICS/IUIS).
The present Research Topic aims to highlight the need to
address controversies and to stress the importance of
nomenclature based on consensus within the immunology
community. Twelve articles are included in this Research
Topic, and are categorized into the following types: two
Original Research (Kalina et al; Magadan et al.), four Reviews
(Gunther et al.; Heger et al.; Ohlin et al.; Sanz et al.), two Mini
Reviews (Chan et al.; Del Fresno et al.), two Opinions (Hsiao
et al.; Zlotnik), and two Perspectives (Bohlson et al.; Busse et al.).
The contributions are briefly covered below with the subtopics
soluble mediators, cell surface receptors, immunoglobulin genes,
cells of the immune system and allergens.SOLUBLE MEDIATORS
The nomenclature of complement components dates back to the
1960s (9), followed by a formalized nomenclature of the later
discovered alternative pathway in 1981 (10). In 2014, an updated
nomenclature of these components with inclusion of newly-
identified receptors was published (11). Despite these
collaborative efforts, in this issue Bohlson et al. identify several
unresolved naming issues. Most importantly, in their present
proposal, the nomenclature for the cleavage fragments of C2 is
brought into line with all other components (C3, C4, C5, Factor
B), such that the smaller fragment is now designated “C2a”and
the larger fragment “C2b”. Additional updates to clusterin, C1
complex activation states recognition molecules (PRMs) and
enzymes of the lectin pathway and regulatory proteins of the
complement system are proposed as an update to the
2014 Nomenclature.
Nomenclature of soluble mediators of the immune system has
been a major challenge, and this was recognized already in theFrontiers in Immunology | www.frontiersin.org 21970s, resulting in the consensus nomenclature of IL-1 and IL-2.
Despite such activities and structured naming of cytokines,
chemokines and their receptors, Zlotnik identifies several
current issues and challenges. These include the ‘neutral’
nomenclature of interleukins, which does not relate to their
(inflammatory or anti-inflammatory) biological activity, or their
evolutionary relationships. Furthermore, the CXC and CC
chemokines are well-defined, but challenges have arisen for
more recently-identified chemokines that are located in other
genomic regions. Thus, in this field there are ongoing
nomenclature challenges, which require clear and perhaps
updated definitions of what would qualify as a novel cytokine
and/or chemokine.CELL SURFACE RECEPTORS
Since the 1980s, Human Leukocyte Differentiation Antigen
(HLDA) workshops have been organized to test and name
clusters of antibodies that reacted with a specific antigen (8).
These cluster of differentiation (CD) markers provided
consistency and uniformity in manuscripts when referring to
identical molecules. CD markers have proven critical for the
identification and isolation of leukocytes and lymphocyte
subsets, the diagnosis and follow-up of hematological
malignancies, autoimmune diseases, and immunodeficiencies,
and the monitoring of cancer immunotherapy. However, there
are important gaps in our knowledge of CD molecule expression
profiles, especially because of the major advances in
multiparametric flow cytometry over the last 30 years. The
paper by Kalina et al. presents a pilot study that shows the
expression patterns of CD1 to CD100 on 47 leukocyte subsets
from the blood, thymus and tonsil, using highly standardized
eight-color flow cytometry. The resulting dataset includes
median antibody binding capacities and percentage of
positivity for all markers on all subsets, and can be explored
online through an interactive CD Maps web resource (www.
hcdm.org). The data presented in this paper will provide a better
picture of the surfaceome of human leukocytes and increase our
understanding of leukocyte biology.
The Ca++-dependent type lectin receptors (C-type lectin
receptors; CLRs) offer an example for Babylonian speech
confusion. Del Fresno et al. explain that there can be up to
seven different names for a single CLR, and that the same name is
used for different CLRs between man and mouse. Here they
analyzed the frequency of use of the different names in the
literature. They suggest the gene name be mentioned for a given
CLR plus the most frequently used name in the abstract of every
paper on the topic. This recommendation can help to overcome
the nomenclature confusion in the field.
A nomenclature for adhesion G protein–coupled receptors
(ADGR) was published several years ago (12). In this
nomenclature the brain-specific angiogenesis inhibitor 1
(BAI1) has been renamed ADGRB1. For this receptor,
expression in macrophages had been reported in 2007. HsiaoDecember 2020 | Volume 11 | Article 621100
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from proteome and transcriptome repositories. None of the
available data sets contained a signal for ADGRB1 in
monocytes/macrophages and this included RNAseq analyses,
which can pick up low abundance transcripts. The study
contributes to clarification of an important issue in the field
of ADGRs.IMMUNOGLOBULIN GENES
Previously-unreported IGHV alleles are often a conspicuous
presence in human datasets of rearranged VDJ gene sequences
(13, 14), but there has been no mechanism by which they can be
named. With support from the ImMunoGeneTics (IMGT)
Group, Ohlin et al. describe processes that can now lead to the
official naming of such sequences.
Magadan et al. describe a new nomenclature to deal with the
complexities of the IGH loci of salmonid species. This task is
made particularly challenging by the fact that the IGH loci of
salmonid species are duplicated on separate chromosomes, and
both loci can rearrange to form functional VDJ genes. In this
study, genomic assemblies of the IGH loci of the Atlantic salmon
and Rainbow trout have been annotated, and IG genes have been
named according to the IMGT positional-within-locus
nomenclature rules.
Busse et al. address the nomenclature challenges that arise
from structural variation in the IGH loci of laboratory mice. The
IMGT positional-within-families mouse IGH nomenclature is
based upon annotations of the IGH locus of the C57BL/6 mouse
genome reference sequence, but this sequence is remarkably
different to the IGH loci of other inbred strains (15, 16). Busse
and colleagues outline the principles that should guide the
development of a new nomenclature to deal with this
challenge. They argue in favor of a non-positional
nomenclature, for this would facilitate the naming of hundreds
of mouse IGHV genes that are now known, but which remain
unmapped and unnamed. Non-positional nomenclature would
also avoid the need for the renaming of some IGHV sequences,
when new genome assemblies identify errors in previous gene
maps. Such changes have resulted in confusion within the
research community in the past.CELLS OF THE IMMUNE SYSTEM
With the availability of an increasing number of new markers,
there is the temptation to define more and more cell subsets.
While in the past a bimodal expression of a cell surface molecule
on a given leukocyte was considered sufficient to define two
subsets, we now require, in addition, a differential transcriptome,
differences in function and, for consolidation, informative
clinical associations.
The renewed attention to B cells during the last decade has
resulted in the identification of many new subsets that areFrontiers in Immunology | www.frontiersin.org 3inconsistently defined and named. Thus, there is an urgent
need for a consistent nomenclature of human B cells to allow
for inter-laboratory interpretability. The very comprehensive
review by Sanz et al. presents a unified approach of
classification based on phenotypic standardization. The authors
propose the use of seven surface markers, using multiparameter
flow cytometry, to define a variety of functionally-distinct B-cell
populations. They also discuss the need for awareness that not all
current surface antigens being utilized for defining distinct B-cell
subsets are sufficiently conclusive. This Perspective is meant to
initiate a discussion in the B-cell community with the aim to
reach an international consensus nomenclature for B cells.
The heterogeneity of monocytes and dendritic cells and the
impact of extensive data sets is covered by Gunther et al.. The
paper points out that many different myeloid cell types and subsets
have been defined on the basis of morphology, cell surface marker
expression and function. Much of this has been confirmed bymass
cytometry, multicolor flow cytometry, and by single cell
sequencing, but additional populations emerged. The pitfalls of
these novel approaches, including misclassifications, are discussed
and unbiased strategies for future research are presented.
The nomenclature of dendritic cells has been difficult because
of a trend to name any cell “dendritic cell”, as long as it could
induce a T cell response. More recently, a more stringent
definition has been used with pDCs, DC1s and DC2s being
considered bona fide DCs. With respect to DC2s, a detailed
analysis has demonstrated there is a subset, which lacks typical
DC features but instead shows markers and functions that are
characteristic of monocytes/macrophages. Heger et al. review the
latest developments in this area and discuss whether or not these
cells belong to the monocyte lineage.ALLERGENS
Since at least the early 1980s leading allergists started to
standardize the naming process for protein allergens that cause
IgE-mediated reactions in humans. The use of the taxonomic
name of the source organism now ensures a consistent
nomenclature that enables communication within allergy
research and clinical care and with external regulatory bodies
(17). Today, applying for a unique name from the WHO/IUIS
Allergen Nomenclature Sub-Committee is a critical step prior to
the publication of data on a novel allergen (5).
The paper by Chan et al. reviews the current procedures and
requirements for the submission of new proteins allergens and the
reasons behind recent changes. These changes are related to
advances regarding a) the amount and route of exposure that
causes a protein to become an allergen; b) the structural biology of
allergen subunits and their contribution to larger complex allergen
structures; c) non-protein allergens such as complex carbohydrates.
This paper will be helpful to colleagues, who plan on submitting
new allergens to the Allergen Nomenclature Committee.
Together, the articles in this Research Topic illustrate the
ongoing need for active governance of existing and assignmentDecember 2020 | Volume 11 | Article 621100
van Zelm et al. Editorial: New Developments in Immunology Nomenclatureof new nomenclatures. There is vast experience in the
immunological research community to deal with such complex
issues. The IUIS Nomenclature committee has a history of
bringing leaders in the field together for timely and open
discussion, and will remain committed to supporting current
and new consensus nomenclature initiatives.AUTHOR CONTRIBUTIONS
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